Axinn, Veltrop & Harkrider LLP
Chad Landmon chairs Axinn’s IP and Food and Drug Administration (FDA) practice groups and focuses his practice on patent litigation and counselling, and FDA law. He maintains a particular focus on patent trial work, having served as a first-chair trial lawyer on multiple cases and having litigated over 50 cases during the past 10 years alone, many of which included products with billions of dollars in annual sales.
For example, Chad led the efforts in fighting off a temporary restraining order and obtaining a favorable claim construction and non-infringement judgment at both the district court and the Federal Circuit in a case involving a product with over $9 billion in annual sales. Recently, Chad has served as lead appellate and trial counsel in obtaining a decision from the Federal Circuit, affirming a decision entered after trial by the US District Court for the District of Delaware (with Federal Circuit Judge William Bryson sitting by designation), that the asserted patents were invalid, removing the patents as a barrier to market entry for Axinn’s client.
By coupling his patent litigation experience with his FDA expertise, Chad enables life sciences clients to develop and execute on patent and FDA strategies to bring products to market in the most efficient and profitable manner. During the course of his career, Chad has worked on eight of the top 10 generic drugs ranked by cost savings and nearly half of the top 100 generic drugs by sales volume. His active FDA litigation practice has enabled clients to maintain their marketing exclusivity rights and obtain market entry. In fact, Chad obtained a court order that has been described as the first time a court has ordered the FDA to approve a product.
Chad was selected as a LMG Life Sciences Life Sciences Star in 2019 for Hatch-Waxman Patent Litigation and was recognized as a Litigation Star by Benchmark Litigation for 2020.